The influence of gastric pentadecapeptide BPC 157 on acute and chronic ethanol administration in mice.
Level 5 - mechanism / opinion, no new human data
Preclinical animal research in mice
PubMed 15381050 · doi:10.1016/j.ejphar.2004.07.112
What was done
Male NMRI mice were treated with the gastric pentadecapeptide BPC 157 at doses of 10 pg (intraperitoneally), 10 ng, or 10 microg (intraperitoneally or intragastrically) under acute and chronic ethanol regimens. For acute toxicity, BPC 157 was administered before or after an acute ethanol dose (4 g/kg intraperitoneally), assessing anesthesia, hypothermia, blood ethanol levels, and mortality over 90 minutes. For chronic exposure, mice consumed 20% ethanol (7.6 g/kg) for 13 days followed by withdrawal provocation on day 14, with BPC 157 given at 0, 3, or 7 hours after cessation and evaluated across 24 hours.
What was found
The abstract reports that acute ethanol produced sustained anesthesia, hypothermia, elevated blood ethanol concentrations, and a 25% fatality rate, all of which were opposed by BPC 157 given before or after ethanol. In the chronic protocol, BPC 157 given at 0, 3, or 7 hours post-cessation attenuated withdrawal signs over 24 hours. Exact numerical values, effect sizes, and statistical variance metrics are not reported in the abstract.
Why it matters
This study suggests that BPC 157 may modulate both acute intoxication and withdrawal effects of ethanol in a rodent model.
Limits
The study is restricted to male mice, limiting direct translation to humans. Sample sizes (n per group), exact numerical changes, and measures of variance or statistical significance are completely omitted from the abstract. Female animals were not tested, and long-term toxicity or durability of effects was not assessed.
Cited by
- supports In animal models, BPC-157 administration reduces signs of acute alcohol intoxication and prevents alcohol withdrawal symptoms.
- supports In mouse data, BPC-157 attenuates alcohol intoxication and alcohol withdrawal.